Take a deep dive into the surprisingly large niche strategy of investing in healthcare royalties with Todd Davis of HealthCare Royalty Partners

Riverside Partners is a lower middle market private equity firm that focuses exclusively on investing in profitable technology and healthcare deals.

Hear a boots-on-the-ground update on the battle against Parkinson’s Disease.

Castle Harlan Co-President Howard Morgan describes his father’s battle with Parkinson’s Disease.

In a candid joint interview, Debra and Leon Black tell the story of what led them to fund the creation of the Melanoma Research Alliance (MRA) with the guidance of their good friend, Michael Milken.

Having his youth under the sun as a sailor, Brendan Dillon was no stranger to sunburn. The senior executive at UBS shares the story of his diagnosis and why he is now involved with the Melanoma Research Alliance.

Lifelong friends tell a story of diminishing hope being replaced by new optimism thanks to treatment techniques backed by the Melanoma Research Alliance.

Mitchell Hollin of LLR Partners discusses his firm’s 2012 investment in Orbis Education.

An executive summary of the Privcap thought-leadership series on private equity investing in America’s dynamic healthcare sector.

Experts at Vestar Capital Partners, Quaker Partners and McGladrey discuss the regulatory, reimbursement and political risks at the heart of healthcare investments.

Big pharmaceutical and biotechnology corporations are on the hunt for acquisitions, and this spells opportunity for Lumira Capital, a Toronto-based venture capital firm.